Inhaled insulin: Clinical efficacy

Diabetes, Obesity and Metabolism, Supplement

Volumn 7, Issue 1, 2005, Pages

  Scherbaum, Werner A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Diabetes; Exubera ; Glycaemic control; Inhaled insulin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; LUNG; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVIEW; SIDE EFFECT;

EID: 27844477779     PISSN: 14657740     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Owens DR. New horizons - alternative routes for insulin therapy. Nat Rev Drug Discov 2002; 1: 529-540.
2. Cefalu WT. Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 2004; 27: 239-246.
3. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
4. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized, prospective 6 year study. Diabetes Res Clin Pract 1995; 8: 103-117.
6. Brain JD. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: safety. Diabetes Obes Metab 2005; 7(Suppl. 1): 14-18.
7. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-2627.
8. Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in subjects with type 1 diabetes: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28: 1630-1635.
9. American Diabetes Association (ADA). Standards of medical care for patients with diabetes. Diabetes Care 2004; 27(Suppl. 1): S15-S35.
10. Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362.
11. DeFronzo RA, Bergenstal RM, Cefalu WT et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled on diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care (in press).
12. Barnett AH. Efficacy and one-year pulmonary safety of inhaled insulin (Exubera®) as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral agent monotherapy Diabetes 2004; 53(Suppl. 2): A107 [Abstract].
13. Rosenstock J, Zinman B, Murphy Q et al. Inhaled insulin (Exubera®) improves glycaemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Annals Intern Med (in press).
14. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
15. American Association of Clinical Endocrinologists (AACE). Medical Guidelines for the Management of Diabetes Mellitus: the AACE System of Intensive Diabetes Self-Management-2002 update (http://www.aace.com/clin/guidelines/diabetes-2002pdf).
16. Häring HU, Joost HG, Laube H et al. Antihperglykärnische Therapie des Diabetes Mellitus Typ 2. Evidenzbasierte Diabetes-Leitlineie DDG. In: Scherbaum WA, Landgraf R eds. Diabetes und Stoffweschsel 2003; 12(Suppl. 2).
17. Bergenstal R. Achieving target HbA1c in studies with inhaled insulin (Exubera®) in type 2 diabetes. Endocr Pract 2004; 10(Suppl. 1): 21-22 [Abstract].
18. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient satisfaction with insulin therapy in type 2 diabetes: a randomized trial of injectable vs. inhaled insulin Diabetes 2002; 51(Suppl. 2): A135 [Abstract].
19. Testa MA, Turner RR, Hayes JF, Simonson DC. Intensive therapy and patient satisfaction in type 1 diabetes: a randomized trial of injected vs. inhaled insulin Diabetologia 2001; 44(Suppl. 1): A4 [Abstract].
20. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient satisfaction and quality of life in type 1 diabetes: a randomized trial of injectable vs. inhaled insulin Diabetes 2001; 50(Suppl. 2): A45 [Abstract].
21. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 1318-1323.
22. Skyler J. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. Diabetes 2004; 53(Suppl. 2): A115 [Abstract].